Personalized medicine will require the initial analysis of the expression levels of tumor markers. This can be achieved by analysis of a biopsy using a cocktail of nanobodies with different ...

Ona Therapeutics SL is accelerating development of its first-in-class antibody-drug conjugate (ADC) therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer ...

Tumor ablation, and ablative radiation therapies such as stereotactic body radiation therapy (SBRT), are mainstays of minimally invasive solid cancer ... cell death markers. However, despite ...

Some of these markers had a proven better sensitivity ... papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

South Korea's DAAN Biotherapeutics has entered an exclusive deal with LigaChem Biosciences to develop a novel tumor-targeting ...

Ona Therapeutics ("Ona"), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support its rapid growth and pipeline ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

For instance, understanding the differences between early and late-stage cancers, how pervasively specific cancers spread, ...

Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology ...